Julio Ordaz Assumes Presidency of AMIIF

The Mexican Association of Pharmaceutical Research Industries (AMIIF) has appointed Julio Ordaz, President and CEO of AstraZeneca Mexico, as its new president for the 2024-2025 term, succeeding Constanza Losada, who has assumed the role of President of Latin America for Bristol Myers-Squibb. Ordaz assumes the presidency amid a new era for the association, marked by a renewed focus on innovation and a commitment to patient health.

"This appointment brings with it a significant responsibility, reaffirming my commitment to continue strengthening collaboration and dialogue among the government, the private sector, and society, as well as promoting equitable access to healthcare for the well-being of the population. Within AMIIF, we acknowledge ourselves as another ally in the public health and innovation landscape to prevent, diagnose, and address global health challenges affecting Mexico and the region," said Ordaz

The appointment of Julio Ordaz brings a wealth of experience and a strong commitment to advancing healthcare innovation, positioning AMIIF for continued growth and impact in the pharmaceutical landscape. With over 15 years of experience in the pharmaceutical industry, including more than a decade at AstraZeneca, Ordaz has prioritized health access and the strengthening of healthcare systems to improve the lives of Mexican families. He currently serves as a board member for the British Chamber of Commerce in Mexico (BRITCHAM) and the National Chamber of the Pharmaceutical Industry (CANIFARMA), as well as being a member of the American Chamber of Commerce (AMCHAM).

"We are confident that we will work as a team with our partners and the incoming government to promote improved conditions and efficient, dynamic regulation. This will enable innovative medications to be placed in the hands of patients, empowering them to enhance their health and quality of life," said Larry Rubin, Executive Director, AMIIF.

Equity is a fundamental aspect of AMIIF's organizational culture, evident in its board restructuring with Ordaz as President, Karla Alcázar as First Vice President, and Rubin as Executive Director. Alcázar, who holds the position of President and CEO at Eli Lilly Latin America, joins Julio Ordaz in guiding the association. “At AMIIF, we are committed to breaking down barriers and reducing gender gaps,” wrote Cristóbal Thompson, Former Executive Director, AMIF for MBN.

AMIIF is a non-profit organization representing the leading research-based pharmaceutical companies operating in Mexico. AMIIF's mission is to promote policies that foster innovation, investment, and sustainable healthcare development for the benefit of patients and society. 

“At AMIIF, and in conjunction with our associated companies, we are committed to promoting scientific research and development to enhance the health conditions and quality of life of the people of Mexico. In keeping with the above, a better quality of life and the well-being of patients will depend on the quality of the health services they receive,” wrote Thompson.